I did something similar as well.
1. uniQure Nv (QURE) 2.6 Billion
2. Regenxbio (RGNX) 1.96 Billion
3. Audentes Theapeatics Inc (BOLD) bought out
4. Solid Biosciences (SLDB) 150 Million note: Failed Clinical though
5. Meira GTx Holdings (MGTX) 670 Million
6. Voyager Therapeutics (VYGR) 500 Million
7. Sarepta Therapeutics (SRPT) 9.5 Billion
Note here I dnt know what these other companies also have in terms of assets etc. But based on a failed clinical the base for this stock is 150 Million. Realistically its prob worth around 375 - 600 Million. If I am not mistaken they will be conducting clinicals soon? If that continues with success then 1 Billion at minimum?
"The successful closing of this transaction is further evidence that our corporate vision and proprietary technology in the gene therapy cancer treatment market are gaining traction with institutional investors," commented Rodney Varner, Chief Executive Officer at Genprex. "This offering will provide additional resources for further development of our technologies, including the planned clinical trial of our Oncoprex™ immunogene therapy in combination with osimertinib (marketed as Tagrisso® by Astra Zeneca) for which we recently received a U.S. FDA Fast Track Designation, and our planned clinical trial of Oncoprex immunogene therapy combined with pemrolizumab (marketed as Keytruda by Merck & Co), both in non-small cell lung cancer, as well as further development of our pre-clinical gene therapy for Type 1 and Type 2 diabetes which we recently in-licensed from the University of Pittsburgh. We are excited to advance these new drug candidates toward potential availability for treatment of these serious diseases in large patient populations with unmet medical needs."
